Discover
Otezla (apremilast) / AmgenOtezla US regulatory estimate: Approval for mild to moderate psoriasis setting by 2022 (Credit Suisse) - Dec 26, 2019 - A subscription to Thomson ONE is required to gain full access to report 68489223; Page no: 4; REPORT TITLE: "U.S. Biotechnology: 2020 outlook: Reevaluating our coverage ahead of the new year”; AUTHOR: Research Department; DATE: 12/13/2019Cosentyx (secukinumab) / NovartisINVIGORATE 2: Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (clinicaltrials.gov) - Dec 24, 2019 - P3; N=380; Not yet recruiting; Sponsor: Novartis PharmaceuticalsTremfya (guselkumab) / J&JChina regulator approves imports of J&J's Tremfya (The New York Times) - Dec 27, 2019 - "China has approved imports of Johnson & Johnson's Tremfya (guselkumab), the National Medical Products Administration said in a notice on Friday. The drug will be used to treat moderate to severe plaque psoriasis in adults who are suitable for systemic therapy..."Otezla (apremilast) / AmgenOtezla pricing projection: $3,400/month for mild to moderate psoriasis setting (Credit Suisse) - Dec 26, 2019 - A subscription to Thomson ONE is required to gain full access to report 68489223; Page no: 4; REPORT TITLE: "U.S. Biotechnology: 2020 outlook: Reevaluating our coverage ahead of the new year”; AUTHOR: Research Department; DATE: 12/13/2019Otezla (apremilast) / AmgenOtezla WW sales projection: $3.4B by 2024 (Credit Suisse) - Dec 26, 2019 - A subscription to Thomson ONE is required to gain full access to report 68489223; Page no: 4; REPORT TITLE: "U.S. Biotechnology: 2020 outlook: Reevaluating our coverage ahead of the new year”; AUTHOR: Research Department; DATE: 12/13/2019Otezla (apremilast) / AmgenOtezla sales projection: $4.8B peak in 2027 (Morgan Stanley) - Dec 24, 2019 - A subscription to Thomson ONE is required to gain full access to report 68506536; Page no: 4; REPORT TITLE: "Amgen Inc- Initiating coverage: Amgen Inc.: Base business optimism drives sentiment into 2020; Resume at overweight”; AUTHOR: Harrison, Matthew, et al; DATE: 12/17/2019
